A Multi-centre, Randomized, Open label, Long-term Study To Investigate Safety of ACT-541468 in Patients with Insomnia Disorder
Latest Information Update: 21 Apr 2022
Price :
$35 *
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational
- Sponsors Idorsia Pharmaceuticals
- 23 Dec 2021 New trial record